Breaking News

Influenza vaccine composition for 2020-2021 northern hemisphere influenza season

The WHO recommendation on the composition of influenza virus vaccines for use in the northern hemisphere 2021-2022 was announced in the WHO Information Meeting and Round-table Discussion with manufacturers and regulatory agencies today, 26 February 2021.

It followed the 7-day virtual Consultation Meeting with Advisers from WHO Collaboration Centres (CCs) and WHO Essential Regulatory Laboratories (ERLs) based on year-round surveillance by the WHO Global Influenza Surveillance and Response System (GISRS).

It is recommended that quadrivalent vaccines for use in the 2021-2022 northern hemisphere influenza season contain the following:

Egg-based Vaccines

  • an A/Victoria/2570/2019 (H1N1)pdm09-like virus;
  • an A/Cambodia/e0826360/2020 (H3N2)-like virus;
  • a B/Washington/02/2019 (B/Victoria lineage)-like virus; and
  • a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.

Cell- or recombinant-based Vaccines

  • an A/Wisconsin/588/2019 (H1N1)pdm09-like virus;
  • an A/Cambodia/e0826360/2020 (H3N2)-like virus;
  • a B/Washington/02/2019 (B/Victoria lineage)-like virus; and
  • a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.

It is recommended that trivalent influenza vaccines for use in the 2021-2022 northern hemisphere influenza season contain the following:

Egg-based Vaccines

  • an A/Victoria/2570/2019 (H1N1)pdm09-like virus;
  • an A/Cambodia/e0826360/2020 (H3N2)-like virus; and
  • a B/Washington/02/2019 (B/Victoria lineage)-like virus.

Cell- or recombinant-based Vaccines

  • an A/Wisconsin/588/2019 (H1N1)pdm09-like virus;
  • an A/Cambodia/e0826360/2020 (H3N2)-like virus; and
  • a B/Washington/02/2019 (B/Victoria lineage)-like virus.

About Team | NewsPatrolling

Comments are closed.

Scroll To Top